Pulmonary arterial hypertension is a devastating disease, which if not interrupted, leads to progressive right-sided heart failure and death within 2 to 3 years after diagnosis. Ivabradine is the first of a heart rate-lowering medication that specifically inhibits the f ion channels in the sinus node. Lowering heart rate with ivabradine has been reported to be safe and free from unpleasant collateral side effects in a case series of pulmonary arterial hypertension patients. This study was conducted aiming to assess the clinical effect of treatment with ivabradine in pulmonary hypertension patients. The current study is an observational study that was carried out on 50 patients suffering from pulmonary hypertension with sinus rhythm during the period from November 2019 to November 2020. These patients received a therapeutic dose of Ivabradine and had basic investigations as 12 leads ECG, 2D ECHO study and 6 MWT performed as baseline and after 3 months of ivabradine therapy. High statistically significant differences were found between baseline and after 3 months clinical characteristics including HR and 6MWT results as well as in NYHA class. Also, comparison of baseline and after 3 months right sided echo parameters revealed statistically significant differences as regards RV mid diameter, TAPSE and PASP. It can be concluded that ivabradin can be used in pulmonary hypertension patients to reduce heart rate and may provide functional capacity in those patiants. However, the exact biological role of ivabradin in pulmonary hypertension need more in-depth investigation.  Large scale multi-center studies are recommended to evaluate the prognostic efficacy of Ivabradin in patients with pulmonary hypertension.